Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triflupromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 8/20 | 1.00 |
| ▸ | TP53 | P04637 | 7/20 | 1.00 |
| ▸ | HTR1A | P08908 | 7/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | DRD1 | P21728 | 6/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 6/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | THPO | P40225 | 5/20 | 1.00 |
| ▸ | MTOR | P42345 | 5/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triflupromazine SCHEMBL32668886 | 1.00 | CYP1A2 (1.00) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| Triflupromazine SCHEMBL30903901 | 0.99 | LMNA (1.00) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| Triflupromazine SCHEMBL317144 | 0.99 | LMNA (1.00) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| Triflupromazine SCHEMBL29419087 | 0.99 | LMNA (1.00) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| Triflupromazine SCHEMBL317145 | 0.98 | CYP1A2 (0.95) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| SCHEMBL7750160 | 0.95 | TP53 (0.91) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| Triflupromazine SCHEMBL28057425 | 0.93 | CYP1A2 (0.87) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| SCHEMBL7346761 | 0.93 | TP53 (0.86) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| SCHEMBL23353457 | 0.92 | TP53 (0.85) | CYP1A2CYP2D6TP53HTR1AADRA2A | |
| Triflupromazine SCHEMBL9055400 | 0.92 | TP53 (0.85) | CYP1A2CYP2D6TP53HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8154 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| US-20260034065-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-02-05 | — | — | US | claimed |
| EP-4658278-A1 | SELECTIVE FIASMA TREATMENT | Valo Health, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| US-12472146-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2025-11-18 | — | — | US | claimed |
| US-20250295671-A1 | Hazardous Agent Injection System | ANTARES PHARMA, INC. (US) | 2025-09-25 | — | — | US | claimed |
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-12357642-B2 | Hazardous agent injection system | ANTARES PHARMA, INC. (US) | 2025-07-15 | — | — | US | claimed |
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACETICALS LTD (NZ) | 2025-07-08 | — | — | US | claimed |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| WO-1987006119-A1 | ANTI-PATHOGENIC BLOOD COLLECTION SYSTEM AND METHOD | AL SIOUFI HABIB | 1987-10-22 | — | — | WO | claimed |
| EP-0174342-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES. | UNIV FLORIDA (US) | 1986-03-19 | — | — | EP | claimed |
| WO-1985003937-A1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1985-09-12 | — | — | WO | claimed |
| US-4536403-A | WITH CARISOPRODOL | ROOKS J F GIRARD | 1985-08-20 | — | — | US | claimed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | claimed |
| US-4478822-A | Drug delivery system utilizing thermosetting gels | MERCK & CO., INC. (US) | 1984-10-23 | — | — | US | claimed |
| US-4474752-A | DIAMINE MODIFIED POLYOXYETHYLENE-POLYOXYPROPYLENE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | claimed |
| US-4407800-A | TRYPANOCIDES | UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 1983-10-04 | — | — | US | claimed |
| US-4249003-A | Process for polycyclic amines | AKTIEBOLAGET LEO (SE) | 1981-02-03 | — | — | US | claimed |
| US-4175119-A | Composition and method to prevent accidental and intentional overdosage with psychoactive drugs | PORTER GARRY L | 1979-11-20 | — | — | US | claimed |